Ammu Jayanthi Viswanathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ammu Jayanthi Viswanathan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aleyamma Mathew
Division of Cancer Epidemiology & Biostatistics, Regional Cancer Centre, Thiruvananthapuram, India
1 shared publication - Anila Tresa Alukal
Division of Gynecological Oncology, Regional Cancer Centre, Thiruvananthapuram, India
1 shared publication - Aswin Kumar
Department of Radiation Oncology, Regional Cancer Center, Thiruvananthapuram, Kerala, India
1 shared publication - Athar Parvez Ansari
Regional Research Institute of Unani Medicine, Chennai (NABH Accredited), New Delhi, India
1 shared publication - Binitha Rajeswari
Department of Pediatric Oncology, Regional Cancer Centre, Trivandrum, Kerala, India
1 shared publication - Dhanya Dinesh
Department of Artificial Intelligence and Data Science, Mar Ephraem College of Engineering and Technology, Kanyakumari, Tamil Nadu 629171, India
1 shared publication
Latest Publications
- Open Access
- 15 November 2022
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 12 (6) , 38-43
Appetite-inducing effect and safety evaluation of Habb-e-Hilteet in patients with Ḍu‘f al-Ishtihā (anorexia): An open prospective clinical trial
Objectives: Anorexia is one among the most prevalent conditions triggering malnutrition, drastic weight loss and serious health issues in people especially older adults. Habb-e-Hilteet is commonly prescribed Unani pharmacopoeial formulation for anorexia. However, no scientific data is available as to its safety and efficacy. The current study assessed the appetite-inducing effect and safety of Habb-e-Hilteet in Ḍu‘f al-Ishtihā (anorexia) patients. Methods: An open prospective clinical trial was carried out in 95 clinically diagnosed anorexia patients of either gender (19-65 yrs old). The study was approved by Institutional ethic committee and conducted in accordance with the GCP guidelines. Habb-e-Hilteet, 1 pill (500mg) was administered orally in patients twice daily for 14 days. The safety of the formulation was assessed by important pathological and biochemical indices and monitoring adverse events. The efficacy was assessed on the basis of improvement in the Simplified Nutritional Appetite Questionnaire (SNAQ) score. Results: Out of 95 patients recruited, 78 completed the trial and 17 patients lost to follow-up. The mean age of patients was 29.8 yrs, with the majority (59.0%) being female. Overall therapeutic response was found to be 96%. A significant (PConclusion: The study results indicate that Habb-e-Hilteet could be a viable treatment option for anorexia with no safety concerns. Keywords: Ḍu‘f al-Ishtihā; Buṭlān al-Shahwa; Anorexia; Habb-e-Hilteet; Unani pharmacopoeal formulation.
- 15 November 2022
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 12 (6) , 38-43
Open AccessAppetite-inducing effect and safety evaluation of Habb-e-Hilteet in patients with Ḍu‘f al-Ishtihā (anorexia): An open prospective clinical trial
Objectives: Anorexia is one among the most prevalent conditions triggering malnutrition, drastic weight loss and serious health issues in people especially older adults. Habb-e-Hilteet is commonly prescribed Unani pharmacopoeial formulation for anorexia. However, no scientific data is available as to its safety and efficacy. The current study assessed the appetite-inducing effect and safety of Habb-e-Hilteet in Ḍu‘f al-Ishtihā (anorexia) patients. Methods: An open prospective clinical trial was carried out in 95 clinically diagnosed anorexia patients of either gender (19-65 yrs old). The study was approved by Institutional ethic committee and conducted in accordance with the GCP guidelines. Habb-e-Hilteet, 1 pill (500mg) was administered orally in patients twice daily for 14 days. The safety of the formulation was assessed by important pathological and biochemical indices and monitoring adverse events. The efficacy was assessed on the basis of improvement in the Simplified Nutritional Appetite Questionnaire (SNAQ) score. Results: Out of 95 patients recruited, 78 completed the trial and 17 patients lost to follow-up. The mean age of patients was 29.8 yrs, with the majority (59.0%) being female. Overall therapeutic response was found to be 96%. A significant (PConclusion: The study results indicate that Habb-e-Hilteet could be a viable treatment option for anorexia with no safety concerns. Keywords: Ḍu‘f al-Ishtihā; Buṭlān al-Shahwa; Anorexia; Habb-e-Hilteet; Unani pharmacopoeal formulation.
- 3 March 2022
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 13 (3) , 580-586
Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation
Clinicopathologic classification of endometrial cancer imperfectly reflects the tumor biology. Pathologic categorization — especially in high-grade tumors — results in an imprecise estimation of the risk of disease, recurrence, and death. Molecular subtyping is emerging as the standard of care in diagnosis and treatment of endometrial cancers. Molecular markers are important prognostic factors in tumor dissemination and early recurrence of endometrial cancers. TP53 mutation is an important prognostic factor for both serous and endometrioid cancers. The study aims to compare the clinical profile and overall survival of endometrial cancers with and without p53 mutation. Sixty-three patients who underwent surgical staging for carcinoma endometrium were included in the study.TP53 mutation status was determined based on p53 expression by immunohistochemistry (IHC) as a p53 wild or p53 mutant type. Data were analyzed for the clinical profile, p53 mutation status on IHC, histological pattern, tumor grade, stage of the disease, lymph node spread, recurrence pattern, treatment received, 2-year disease-free survival, and overall survival. Recurrence was noted in 12.7% patients after 2-year follow-up, of which 75% patients had p53 mutation. Significant association was seen between p53 expression and high-grade tumors, stage, cervical involvement, and adnexal involvement. The 2-year overall survival of the p53 wild type was 97.2% and the p53 mutant type was 91.7%. The 2-year disease-free survival for the p53 wild type was 94.3% and the disease-free survival of the p53 mutant variety was 83.5%. The 2-year disease-free survival for endometrioid carcinoma with p53 wild type was 100% and p53 mutant variety was 86.2% (p value 0.033). About 15.9% (10) patients were reassigned to the high-risk group needing chemotherapy and radiation according to the ESGO ESTRO 2021 consensus classification, due to their p53 mutation status. IHC to assess somatic p53 mutation may be done in endometrial biopsies irrespective of their histology. This may help to identify that the aggressive tumors thereby help in tailoring surgery, planning adjuvant treatment, and follow-up.
- 3 March 2022
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 13 (3) , 580-586
Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation
Clinicopathologic classification of endometrial cancer imperfectly reflects the tumor biology. Pathologic categorization — especially in high-grade tumors — results in an imprecise estimation of the risk of disease, recurrence, and death. Molecular subtyping is emerging as the standard of care in diagnosis and treatment of endometrial cancers. Molecular markers are important prognostic factors in tumor dissemination and early recurrence of endometrial cancers. TP53 mutation is an important prognostic factor for both serous and endometrioid cancers. The study aims to compare the clinical profile and overall survival of endometrial cancers with and without p53 mutation. Sixty-three patients who underwent surgical staging for carcinoma endometrium were included in the study.TP53 mutation status was determined based on p53 expression by immunohistochemistry (IHC) as a p53 wild or p53 mutant type. Data were analyzed for the clinical profile, p53 mutation status on IHC, histological pattern, tumor grade, stage of the disease, lymph node spread, recurrence pattern, treatment received, 2-year disease-free survival, and overall survival. Recurrence was noted in 12.7% patients after 2-year follow-up, of which 75% patients had p53 mutation. Significant association was seen between p53 expression and high-grade tumors, stage, cervical involvement, and adnexal involvement. The 2-year overall survival of the p53 wild type was 97.2% and the p53 mutant type was 91.7%. The 2-year disease-free survival for the p53 wild type was 94.3% and the disease-free survival of the p53 mutant variety was 83.5%. The 2-year disease-free survival for endometrioid carcinoma with p53 wild type was 100% and p53 mutant variety was 86.2% (p value 0.033). About 15.9% (10) patients were reassigned to the high-risk group needing chemotherapy and radiation according to the ESGO ESTRO 2021 consensus classification, due to their p53 mutation status. IHC to assess somatic p53 mutation may be done in endometrial biopsies irrespective of their histology. This may help to identify that the aggressive tumors thereby help in tailoring surgery, planning adjuvant treatment, and follow-up.
- Open Access
- 26 June 2020
- Published by Wiley
Severe infections during maintenance chemotherapy of childhood Acute Lymphoblastic Leukemia and their correlation with serum immunoglobulin status
Background: Few studies have looked into the impact of hypoglobulinaemia on infectious complications in childhood acute lymphoblastic leukemia (ALL). We conducted this prospective study to analyse the profile of severe infections during maintenance chemotherapy in Indian children and their correlation with serum immunoglobulin levels. Methodology: Children ≤14 years with ALL on maintenance chemotherapy were recruited and serum immunoglobulin levels were measured at the time-of-recruitment in this study conducted between 1st April 2018 and 31st March 2019. Children were followed up for severe infection for a period of 6 months or till completion of treatment whichever was later. Statistical analysis was done to find out risk factors of severe infection including serum immunoglobulin status. Results: We recruited 199 children undergoing maintenance chemotherapy (58, 52, 47, and 42 children in 0-6, 7-12, 13-18 and 19-24 months of maintenance period) and followed them up for a mean (SD) 9.7(2.961) months. 56.8%, 80.4%, and 86.4% children had hypo-IgG, hypo-IgA, and hypo-IgM at the time-of-recruitment. Ninety-one (45.7%) children developed 147 episodes of severe infections of which 54 (59.3%) were respiratory. Univariate analysis showed younger age, female gender and normal IgG group had significantly increased risk of severe infection (P=0.024, 0.007, 0.049, respectively), in multivariate analysis female gender had significantly increased risk of severe infection (P=0.025). Conclusion: Significant proportion of Indian children on ALL maintenance chemotherapy developed severe infection and hypoglobulinaemia. However, hypoglobulinaemia did not significantly increase the risk of severe infection. Younger children and female gender had significantly increased risk of severe infection during maintenance.
- 26 June 2020
- Published by Wiley
Open AccessSevere infections during maintenance chemotherapy of childhood Acute Lymphoblastic Leukemia and their correlation with serum immunoglobulin status
Background: Few studies have looked into the impact of hypoglobulinaemia on infectious complications in childhood acute lymphoblastic leukemia (ALL). We conducted this prospective study to analyse the profile of severe infections during maintenance chemotherapy in Indian children and their correlation with serum immunoglobulin levels. Methodology: Children ≤14 years with ALL on maintenance chemotherapy were recruited and serum immunoglobulin levels were measured at the time-of-recruitment in this study conducted between 1st April 2018 and 31st March 2019. Children were followed up for severe infection for a period of 6 months or till completion of treatment whichever was later. Statistical analysis was done to find out risk factors of severe infection including serum immunoglobulin status. Results: We recruited 199 children undergoing maintenance chemotherapy (58, 52, 47, and 42 children in 0-6, 7-12, 13-18 and 19-24 months of maintenance period) and followed them up for a mean (SD) 9.7(2.961) months. 56.8%, 80.4%, and 86.4% children had hypo-IgG, hypo-IgA, and hypo-IgM at the time-of-recruitment. Ninety-one (45.7%) children developed 147 episodes of severe infections of which 54 (59.3%) were respiratory. Univariate analysis showed younger age, female gender and normal IgG group had significantly increased risk of severe infection (P=0.024, 0.007, 0.049, respectively), in multivariate analysis female gender had significantly increased risk of severe infection (P=0.025). Conclusion: Significant proportion of Indian children on ALL maintenance chemotherapy developed severe infection and hypoglobulinaemia. However, hypoglobulinaemia did not significantly increase the risk of severe infection. Younger children and female gender had significantly increased risk of severe infection during maintenance.